Journal article
The road to avibactam: The first clinically useful non-β-lactam working somewhat like a β-lactam
- Abstract:
-
Avibactam, which is the first non-β-lactam β-lactamase inhibitor to be introduced for clinical use, is a broad-spectrum serine β-lactamase inhibitor with activity against class A, class C, and, some, class D β-lactamases. We provide an overview of efforts, which extend to the period soon after the discovery of the penicillins, to develop clinically useful non-β-lactam compounds as antibacterials, and, subsequently, penicillin-binding protein and β-lactamase inhibitors. Like the β-lactam inhib...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
AstraZeneca,
More from this funder
Biochemical Society
More from this funder
Biotechnology and Biological Sciences Research Council
More from this funder
Bibliographic Details
- Publisher:
- Future Science Ltd Publisher's website
- Journal:
- Future Medicinal Chemistry Journal website
- Volume:
- 8
- Issue:
- 10
- Pages:
- 1063-1084
- Publication date:
- 2016-06-01
- Acceptance date:
- 2016-05-06
- DOI:
- EISSN:
-
1756-8927
- ISSN:
-
1756-8919
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:631143
- UUID:
-
uuid:387bb618-ff2e-4cbb-adc2-d38cb9d37ac6
- Local pid:
- pubs:631143
- Source identifiers:
-
631143
- Deposit date:
- 2016-08-16
Terms of use
- Copyright holder:
- Wang D Y et al
- Copyright date:
- 2016
- Notes:
- This article is distributed under the terms of the Creative Commons Attribution License 4.0 which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. To view a copy of the license, visit http://creativecommons.org/licenses/by/4.0/
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record